Tony Berberabe, MPH

In this population, median progression-free survival was nearly 40 months.

Positive data has been seen with CAR T-cell therapy in patients with indolent lymphoma.

Longer follow-up is needed to determine the potential of CAR T-cell therapies in difficult-to-treat malignancies.

The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.

A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.

Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).